Skip to main content
. 2016 Mar 8;11(3):e0150336. doi: 10.1371/journal.pone.0150336

Fig 5. Anti-tumor effects of targeting ASPH in a rat intrahepatic CCA model of intrahepatic growth as well as subcutaneous tumor growth in nude mice xenograft with a human H1 CCA cell line.

Fig 5

(A) Gross morphology and histology (H&E staining) of rat livers inoculated with BDE-Neu-CL#24-shRNA-luciferase (shLuc) or BDE-Neu-CL#24-shRNA-ASPH (shASPH). (B) Tumor volume in rat livers of BDE-Neu cell clone (#24) generated intrahepatic CCA tumors. (C) (Upper) Expression of ASPH, activated Notch1, HES1, and HEY1 in shLuc and shASPH treated in BDE-Neu-CL#24 generated tumors. (Lower) Relative expression abundance was shown by the density measurements. (D) (Upper) Representative IHC images of activated Notch1 in shLuc and shASPH treated rat intrahepatic CCA. (Lower) Number of positive nuclei containing an activated Notch1 signal was calculated. (E) H1 xenograft tumor growth rate and progression was determined in nude mice receiving DMSO or MO-I-1151 treatment every other day at 25 mg/kg. **, p <0.01; *, p <0.05.